Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder

This study has been completed.

First Received: September 27, 2005 Last Updated: January 12, 2006 History of Changes

Sponsored by:	Cephalon
Information provided by:	Cephalon
ClinicalTrials.gov Identifier:	NCT00233675

Purpose

To assess the long-term safety and tolerability of tiagabine treatment in patients with generalized anxiety disorder (GAD).

Condition	Intervention	Phase
General Anxiety Disorder	Drug: GABITRIL (tiagabine hydrochloride; CEP-6671)	Phase III

MedlinePlus related topics: Anxiety

Drug Information available for: Tiagabine Tiagabine hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment
Official Title:	A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety of GABITRIL at Dosages Up to 16mg/Day in Adults With Generalized Anxiety Disorder

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00233675

Show 28 Study Locations

Sponsors and Collaborators

Cephalon

Investigators

Study Director:

Charles Brown, MD

Cephalon

More Information

No publications provided

Study ID Numbers:	C6671A/301/AX/US
Study First Received:	September 27, 2005
Last Updated:	January 12, 2006
ClinicalTrials.gov Identifier:	NCT00233675 History of Changes
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Neurotransmitter Agents
Anxiety Disorders
Tiagabine

Mental Disorders
GABA Agonists
Anticonvulsants

Additional relevant MeSH terms:

Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Disease
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Pharmacologic Actions
Pathologic Processes
Anxiety Disorders

Mental Disorders
Tiagabine
GABA Agonists
Therapeutic Uses
GABA Agents
Central Nervous System Agents
Anticonvulsants

ClinicalTrials.gov processed this record on May 07, 2009